drugset / Trial / NCT05324319
Homologous vs Heterologous Third Vaccination in Kidney Transplant Recipients Kidney Transplant Recipients
RandomizedParallel-groupDouble-blindPrevention
Summary
Randomized-controlled trial comparing homologous (mRNA vaccine) vs. heterologous (vector vaccine) for third SARS-CoV-2 vaccine dose in kidney transplant recipients not responding to initial prime-boost vaccination with an mRNA vaccine.
Timeline
- Start
- 2021-06-15
- Primary completion
- 2022-07-31
- Completion
- 2022-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ad26COVS1 | Vaccine | — | — |
| Comparator | BNT162b2 | Messenger RNA (mRNA) | — | — |
| Subject | ChAdOx1 SARS2 Vaccine | Unknown | — | — |
| Comparator | mRNA-1273 | Messenger RNA (mRNA) | — | — |